Fetal fibronectin testing not always so accurate

Article

The specificity and sensitivity of fetal fibronectin testing are significantly lower for predicting delivery at less than 30 weeks gestation in asymptomatic women with cervical cerclage.

The specificity and sensitivity of fetal fibronectin (fFN) testing are significantly lower for predicting delivery at less than 30 weeks' gestation in asymptomatic women with cervical cerclage than they are in women without cerclage, according to a retrospective, observational study from London.

The study included 910 asymptomatic women at high risk for preterm birth who were referred to specialist antenatal clinics between the years 1997 and 2007 and who underwent fFN testing between 23 and 27 weeks' gestation.

Researchers calculated a specificity of 77% in women with cerclage in situ versus 90% in women without (P≤.00001) and a sensitivity of 60% in women who received the procedure versus 78.6% in women who did not (P>.4). The negative predictive value (NPV) of the fFN test, however, was greater than 98% in both groups.

Duhig KE, Chandiramani M, Seed PT, et al. Fetal fibronectin as a predictor of spontaneous preterm labour in asymptomatic women with a cervical cerclage. BJOG. 2009;116:799-803.

Recent Videos
Eran Bornstein, MD, highlights early signs of preeclampsia clinicians need to know | Image Credit: northwell.edu.
Eran Bornstein, MD explains the need for first trimester preeclampsia screening | Image Credit: northwell.edu.
Veerle Bergink, MD, PhD, highlights familial links of postpartum psychosis | Image Credit: profiles.mountsinai.org.
Ivie Odiase, MD
Susan Khalil, MD
Sharon Erdrich, PhD, discusses why oral health should be routine in health care | Image Credit: linkedIn.com.
Sharon Erdrich, PhD, highlights oral health's impact on chronic pain | Image Credit: linkedIn.com.
Fiona Gilbert, MA, MB, discusses breast cancer screening for dense breasts | Image Credit: newn.cam.ac.uk
Expert discussions from the 2025 ACOG meeting | Image Credit: © stevengaertner - © stevengaertner - stock.adobe.com.
Trina Mansour, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.